Form D · Biotechnology
Immune Design Corp.
Seattle, WA · CIK 0001437786
Offering snapshot reported Jun 12, 2014 · SEC filing
- Reported sold
- $17.5K Offering amount: $17.5K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 10, 2011 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 12, 2014 | Initial | $17,500 | No comparison | 1 | SEC filing |
| Jun 11, 2014 | Initial | $10 | No comparison | 1 | SEC filing |
| Jun 11, 2014 | Amendment | $10,500 | -$3,500vs Jul 29, 2009 | 1 | SEC filing |
| Oct 31, 2013 | Initial | $48,450,000 | No comparison | 8 | SEC filing |
| Jan 30, 2013 | Amendment | $34,000,000 | $10,625,008vs Oct 5, 2011 | 6 | SEC filing |
| Oct 5, 2011 | Amendment | $23,374,992 | $11,374,992vs Aug 5, 2010 | 6 | SEC filing |
| Aug 26, 2010 | Amendment | $12,749,996 | $749,996vs Aug 5, 2010 | 6 | SEC filing |
| Aug 5, 2010 | Initial | $12,000,000 | No comparison | 5 | SEC filing |
| Oct 6, 2009 | Initial | $10,500 | No comparison | 1 | SEC filing |
| Jul 29, 2009 | Initial | $14,000 | No comparison | 1 | SEC filing |
| Jul 8, 2009 | Amendment | $14,000,000 | No comparison | 4 | SEC filing |
| Jun 13, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jun 13, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-219014
Source: Form D, filed Jun 12, 2014. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Brian Atwood | Director |
| David Baltimore | Director |
| Franklin Berger | Director |
| Stephen R. Brady | Executive |
| Bruce V Carter | Director |
| Thomas Dubensky | Executive |
| Sammy Farah | Executive |
| Wayne Gombotz | Executive |
| Richard T. Kenney | Executive |
| Richard Klausner | Director |
| David Parker | Executive |
| Carlos V. Paya | Director, Executive |
| Ed Penhoet | Director |
| Edward Penhoet | Director |
| Roger Perlmutter | Director |
| Steven Reed | Director, Executive |
| Steve Reed | Director, Executive |
| James Rickey | Executive |
| Paul Rickey | Executive |
| William Ringo | Director |
| Alain V Schreiber | Director |
| Peter Svennilson | Director |
| Jan Henrik Ter Meulen | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1616 Eastlake Ave. E Suite 310
Seattle, WA, 98102
Seattle, WA, 98102